# Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/ALEC/alector-to-participate-in-the-goldman-sachs-46th-annual-global-healthcare-confer-5d98df60
Ticker: ALEC
Company: Alector
Source: Alector
Published: 2025-06-03 12:00 EST
## Summary

Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on...

## Article Body
Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2024, at 8:40 am ET.

A live webcast of the fireside chat will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com . A replay will be available on the Alector website for 90 days following the event.

About Alector Alector is a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of genetically validated programs that aim to remove toxic proteins, replace deficient proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector’s product candidates seek to treat a range of indications, such as frontotemporal dementia, Alzheimer’s disease, and Parkinson's disease. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being selectively applied to its next-generation product candidates and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit www.alector.com .

Alector Contacts: Alector Katie Hogan 202-549-0557 katie.hogan@alector.com

Argot Partners (media) David Rosen 646-461-6387 alector@argotpartners.com

Argot Partners (investors) Laura Perry 212-600-1902 alector@argotpartners.com
## Recent Company News
- 2026-05-07 20:05 EST — [Alector Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/ALEC/alector-reports-first-quarter-2026-financial-results-and-provides-business-updat-145e9f5a) — Source: Alector
- 2026-04-29 20:05 EST — [Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis](https://biopharmsignal.com/news/ALEC/alector-to-discontinue-phase-2-progress-ad-trial-of-nivisnebart-al101-gsk4527226-1b3ecd87) — Source: Alector
- 2026-02-25 21:05 EST — [Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update](https://biopharmsignal.com/news/ALEC/alector-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-71948925) — Source: Alector
- 2026-02-24 13:00 EST — [Alector to Participate in the TD Cowen 46th Annual Health Care Conference](https://biopharmsignal.com/news/ALEC/alector-to-participate-in-the-td-cowen-46th-annual-health-care-conference-37db60ef) — Source: Alector
- 2025-12-12 21:05 EST — [Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer](https://biopharmsignal.com/news/ALEC/alector-appoints-neil-berkley-as-chief-financial-officer-and-chief-business-offi-a31ca2cf) — Source: Alector
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)